Recent advances of Phosphodiesterase 4B in cancer

Expert Opin Ther Targets. 2023 Feb;27(2):121-132. doi: 10.1080/14728222.2023.2183496. Epub 2023 Feb 28.

Abstract

Introduction: Phosphodiesterase 4B (PDE4B) is a crucial enzyme in the phosphodiesterases (PDEs), acting as a regulator of cyclic adenosine monophosphate (cAMP). It is involved in cancer process through PDE4B/cAMP signaling pathway. Cancer occurs and develops with the regulation of PDE4B in the body, suggesting that PDE4B is a promising therapeutic target.

Areas covered: This review covereed the function and mechanism of PDE4B in cancer. We summarized the possible clinical applications of PDE4B, and highlighted the possible ways to develop clinical applications of PDE4B inhibitors. We also discussed some common PDEs inhibitors, and expected the development of combined targeting PDE4B and other PDEs drugs in the future.

Expert opinion: The existing research and clinical data can strongly prove the role of PDE4B in cancer. PDE4B inhibition can effectively increase cell apoptosis, inhibit cell proliferation, transformation, migration, etc., indicating that PDE4B inhibition can effectively inhibit the development of cancer. Other PDEs may antagonize or coordinate this effect. As for the further study on the relationship between PDE4B and other PDEs in cancer, it is still a challenge to develop multi-targeted PDEs inhibitors.

Keywords: Cancer; cyclic adenosine monophosphate; inhibitors; phosphodiesterase 4B; phosphodiesterases.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Cyclic Nucleotide Phosphodiesterases, Type 4* / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 4* / pharmacology
  • Humans
  • Neoplasms* / drug therapy
  • Signal Transduction

Substances

  • Cyclic Nucleotide Phosphodiesterases, Type 4